Ley-Tomas J, Xicotencatl-Tellez A, Garcia-Cruz M, Jimenez-Chobillon M
Front Allergy. 2024; 5:1462985.
PMID: 39665076
PMC: 11631927.
DOI: 10.3389/falgy.2024.1462985.
Laidlaw T
Curr Opin Allergy Clin Immunol. 2024; 25(1):41-46.
PMID: 39641750
PMC: 11695142.
DOI: 10.1097/ACI.0000000000001051.
Bolk K, Wise S
J Pers Med. 2024; 14(4).
PMID: 38673059
PMC: 11051580.
DOI: 10.3390/jpm14040432.
Taniguchi M, Sato A, Mita H
Front Allergy. 2023; 4:1145809.
PMID: 38026126
PMC: 10667677.
DOI: 10.3389/falgy.2023.1145809.
Plaza Moral V, Alobid I, Alvarez Rodriguez C, Blanco Aparicio M, Ferreira J, Garcia G
Open Respir Arch. 2023; 5(4):100277.
PMID: 37886027
PMC: 10598226.
DOI: 10.1016/j.opresp.2023.100277.
Aspirin-exacerbated respiratory disease: Updates in the era of biologics.
Mullur J, Buchheit K
Ann Allergy Asthma Immunol. 2023; 131(3):317-324.
PMID: 37225000
PMC: 10524829.
DOI: 10.1016/j.anai.2023.05.016.
Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
Laidlaw T, Boyce J
J Allergy Clin Immunol. 2022; 151(2):301-309.
PMID: 36184313
PMC: 9905222.
DOI: 10.1016/j.jaci.2022.08.021.
Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
Buchheit K, Sohail A, Hacker J, Maurer R, Gakpo D, Bensko J
J Allergy Clin Immunol. 2022; 150(2):415-424.
PMID: 35460728
PMC: 9378638.
DOI: 10.1016/j.jaci.2022.04.007.
Baseline Conservative and Surgical Management in the Treatment of NSAID-Exacerbated Respiratory Disease.
Sillanpaa S, Numminen J
Front Allergy. 2022; 2:659887.
PMID: 35387049
PMC: 8974786.
DOI: 10.3389/falgy.2021.659887.
Local and Systemic Production of Pro-Inflammatory Eicosanoids Is Inversely Related to Sensitization to Aeroallergens in Patients with Aspirin-Exacerbated Respiratory Disease.
Potaczek D, Trad G, Sanak M, Garn H, Mastalerz L
J Pers Med. 2022; 12(3).
PMID: 35330446
PMC: 8955638.
DOI: 10.3390/jpm12030447.
Emerging Biomarkers Beyond Leukotrienes for the Management of Nonsteroidal Anti-inflammatory Drug (NSAID)-Exacerbated Respiratory Disease.
Rhyou H, Nam Y, Park H
Allergy Asthma Immunol Res. 2022; 14(2):153-167.
PMID: 35255534
PMC: 8914608.
DOI: 10.4168/aair.2022.14.2.153.
Recent Insights into the Management of Inflammation in Asthma.
Rupani H, Fong W, Kyyaly A, Kurukulaaratchy R
J Inflamm Res. 2021; 14:4371-4397.
PMID: 34511973
PMC: 8421249.
DOI: 10.2147/JIR.S295038.
Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.
Eid R, Yan C, Stevens W, Doherty T, Borish L
J Allergy Clin Immunol. 2021; 148(2):309-318.
PMID: 34364539
PMC: 8363117.
DOI: 10.1016/j.jaci.2021.06.016.
Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease.
Buchheit K, Laidlaw T, Levy J
J Allergy Clin Immunol. 2021; 148(2):348-350.
PMID: 34174296
PMC: 9022378.
DOI: 10.1016/j.jaci.2021.06.019.
Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease.
Sweis A, Locke T, Ig-Izevbekhai K, Lin T, Kumar A, Douglas J
Allergy Asthma Proc. 2021; 42(2):136-141.
PMID: 33685558
PMC: 8133012.
DOI: 10.2500/aap.2021.42.210002.
Aspirin-exacerbated respiratory disease: Update on medical management.
White A, Woessner K, Simon R
World J Otorhinolaryngol Head Neck Surg. 2020; 6(4):241-247.
PMID: 33336180
PMC: 7729248.
DOI: 10.1016/j.wjorl.2020.07.009.
Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost.
Workman A, Bleier B
World J Otorhinolaryngol Head Neck Surg. 2020; 6(4):230-234.
PMID: 33336178
PMC: 7729237.
DOI: 10.1016/j.wjorl.2020.06.002.
Olfactory outcomes in the management of aspirin exacerbated respiratory disease related chronic rhinosinusitis.
Spielman D, Overdevest J, Gudis D
World J Otorhinolaryngol Head Neck Surg. 2020; 6(4):207-213.
PMID: 33336175
PMC: 7729240.
DOI: 10.1016/j.wjorl.2020.07.001.
The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of....
Stevens W, Jerschow E, Baptist A, Borish L, Bosso J, Buchheit K
J Allergy Clin Immunol. 2020; 147(3):827-844.
PMID: 33307116
PMC: 7980229.
DOI: 10.1016/j.jaci.2020.10.043.
Local immunoglobulin production in nasal tissues: A key to pathogenesis in chronic rhinosinusitis with nasal polyps and aspirin-exacerbated respiratory disease.
Buchheit K, Hulse K
Ann Allergy Asthma Immunol. 2020; 126(2):127-134.
PMID: 33065294
PMC: 8210467.
DOI: 10.1016/j.anai.2020.09.016.
